Editor for The Biotech Forum, the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade.
Please go to biotechforumsa.com for more on the Biotech Forum service available through SeekingAlpha. For Free Investment Reports on a variety of topics go to bretjenseninvests.com
Jonathan Moreland is the founder and Director of Research at InsiderInsights.com, which produces the weekly InsiderInsights Newsletter, and offers institutional strength, real-time insider data and analytics via a subscription Data Module and APIs. He is also principal of Insider Asset Management llc, a registered investment advisor in New York State, and a past contributor to TheStreet.com, Minyanville, and other financial outlets.
A fundamental analyst with an MBA in finance, Mr. Moreland identified insider data over 25 years ago as an excellent first screen to determine where to focus his research efforts. He is quoted frequently in the media for his insider analysis, and stock recommendations stemming from it. He is also author of Profit From Legal Insider Trading (Dearborn 2001), and has a new book due out with Wiley.
Mr. Moreland is currently on a mission to get investors to expect more from insider data than the commodity feeds they rely on from their Bloomberg terminals, Yahoo!Finance, and other financial websites.
My name is Dr Kanak Kanti De, MBBS, MD, PhD, retired medical practitioner, cancer survivor, healthcare sector investor, over 30 years' experience in the sector both in India and the United States. I write/have written on Motley Fool, SeekingAlpha, Benzinga, and on Forbes. I am consistently ranked high on TipRanks, although I don't like their ranking system. My portfolio has consistently beat the various indices for years. Email me to discuss my articles, or for just an adda (Bengali for informal chat) firstname.lastname@example.org.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Alex Cho is a top contributor on Seeking Alpha in both the long ideas and technology section of the website. Alex Cho's articles have been featured on The Motley Fool, The Street, and Benzinga. Alex Cho has been featured on ValueWalk's throwback Thursday for his analysis on Apple. Furthermore, Alex Cho's financial expertise ranks him in the top 100 on TipRanks, and his recommendations have a 80% success rate according to Tip Ranks.
To reach out to him for business opportunities, to share ideas, guest writing opportunities, consulting opportunities e-mail him at email@example.com
I am a psychologist at the University of Massachusetts/Amherst. I am on our campus’s Institutional Review Board, which must conclude that proposed studies involving human subjects are conducted ethically and are designed well enough so that any risks involved are justified by the likely benefits obtained.
I teach about analytical reasoning, leadership skills, reconciling apparently incompatible positions, designing, implementing, and evaluating policies, and how to critically evaluate competing health claims based on the samples studied and methods of data collection and analysis used.
Most of my investments involve owning medical industry stocks.
I have a private small company with a few different revenue streams. I survive off of one particular stream and invest the other smaller streams into the market.
I consider myself a longterm value investor and am not risk averse. I have three seperate portfolios each holding one third of my capital.
My goal was to create a multiframed method of analysis that might allow the average retail investor to pick investments that have a high probability of doubling or tripling. I am willing to cut against the grain and take contrarian deep value bets based on price value inefficiencies. I would like to compound at 30% average yearly gains in an all of my accounts. I have had 2 years of compounding my money at over 300% in these accounts so I would be ahead of my current benchmarks. As of end of 2013.
However, I do not expect to be able to repeat my results over the long term by trading. In fact I expect to sometimes underperform the market as many of my ideas might take time to come to fruition. I will often use arbitrage opportunities or short term swings for smaller gains. I am working on fine tuning my methodology but I believe it is unique and should produce the minimum average of 30%. I am currently ahead in this race and can withstand a correction as my portfolio grows quickly. I am also willing to get defensive if need be to protect capital or even go 50%cash. I run this as a very concentrated portfolio.
One third of my capital goes in a DRIP that I average in monthly to seven companies. I change these companies yearly based on valuation and position size. I grow positions here over time and never want to hold more than 30 companies in this account.
One third goes into long term companies that I see huge growth potential.
One third is in speculative bio-tech, tech and just about anything else where I can understand the financial statement sheets on and has great possible momentum and catalysts.
I often find myself going against the current trends in the market as I see opportunity in others fear. That said I seem to invest in around 15 stocks at a time and try to focus investments into the company at the best value. I hope to earn a healthy return over the next ten years to twenty years.
I am also interested in working in the industry as a career change and am always open to advice. Anyone out there want a 36 year old intern with advanced degrees in other areas?
My main skills are finding deep value opportunities and lucrative swing trade opportunities. I seem to have found a lot of bottom entries even in today's markets. I am willing to learn, enjoy games/game theory, love to read and solve problems.
I am working on starting a limited partnership for 2015 or 2016 so that I can share my gifts with family and friends.
"What looks like a horrible disaster now could be an awesome opportunity." "Buy Cheap when the big funds and others are giving it away"
All the Best,
I worked in New York's financial sector for almost exactly 20 years, mostly as a healthcare analyst (drugs, biotech, and medical devices), but also as an assistant research director, portfolio manager, and options strategist. My last formal job had me in charge of Value Line's premium priced "Select" and "Special Situation" products. The former highlights the company's top stock pick of each month and the latter introduces relatively small companies. I quit that job in June, 2009 for reasons that a dozen or so confidentiality agreements preclude my discussing. In September of that year, I launched 3DimensionalResearch.com (3DR), which allows me to continue doing what I was doing previously.
I am a strong believer in maximum transparency, in both personal and business relationships. So, in that vein:
A google search will show that my former employer sued 3DR and me in November, 2009 for copyright infringement, hot news misappropriations, and the proverbial kitchen sink. Although a search won't show this, unfortunately, I represented myself in a federal courtroom in December and, in accordance with the judge's instructions, the case was settled in a matter of minutes.
Additional Disclosure: 3DR has been a financial failure thus far, in terms of getting subscribers. I detest marketing and few people want to pay for information anymore, least of all from a no-name website. That said, the vast majority of my recommendations have done very well and my personal portfolio is doing extraordinarily well (65.5% in 2013) since I tend to follow most of my own recommendations, the "event driven special situations," in particular.
I am an independent equity research analyst and consultant. I focus on finding small-cap biotech stocks where I believe there is favorable risk / reward because of misinformation, lack of information, or a potential fundamental turnaround. I provide detail analysis for investors and investor relations companies. I also provide due diligence and advisory services to companies. Some names I write on I invest in personally and will disclose my position. Names that have hired me to provide due diligence or advisory services I will disclose a business relationship. I previously worked for Zacks Investment Research from 2003 to 2015 as a Senior Biotechnology Analyst. Prior to Zacks, I spent 1999 to 2002 managing money with Eastover Capital in Charlotte, NC where I focused on large-cap equities, specializing in healthcare, energy, and technology. Prior to joining Eastover, I worked as a research scientist for TechLab, Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases, between 1995 and 1998. I also spent a year working at the Fralin Biotechnology Center, and a year working for a cancer researcher while at Virginia Tech. I have a B.S. in Biochemistry from Virginia Tech, with a B.A in Chemistry and a minor in Math. I have a M.B.A. in Finance, with a concentration in Securities Analysis, from Wake Forest University. I hold the Chartered Financial Analyst (CFA) designation.
I am a physician and vitamin D expert. I am a graduate of the University of North Carolina School of Medicine. In my 35 year career in medicine, I have practiced emergency medicine, general practice and psychiatry.
In 2003, I established the Vitamin D Council, a non-profit dedicated to educating the public and health professionals about vitamin D. I frequently speak about vitamin D and have spoken at the annual meeting of the American Association for the Advancement of Science. I recently served as a "visiting professor" for Marshall University School of Medicine's 25th Annual Research Day.
I have been studying, writing and lecturing about vitamin D for more than 12 years. The Vitamin D Council's website gets over 2.5 million users per year. If you Google my name, "John Cannell", you will get over 60,000 hits, almost all about vitamin D. If you search for "Cannell JJ" on Google Scholar, you will see I have written more than a dozen peer-reviewed scientific articles about vitamin D. Three of my scientific articles (two about influenza and vitamin D and one about autism and vitamin D) are the most cited articles in the history of their respective journals.
I am a Portuguese independent trader, analyst and algorithmic trading expert, having worked for both sell side (brokerage) and buy side (fund management) institutions.
I've been trading professionally for about 20 years and also launched www.thinkfn.com in 2004. Thinkfn (Think Finance) carries thousands of educational articles on finance and the markets.
I trade futures, stocks from the long and short side, forex and options. I trade both discretionary and fully automated systems (Metatrader, Quantshare and others).
I can be reached at paulo.santosATthinkfn.com or followed on Twitter at twitter.com/ThinkFinance999
It is very hard or impossible to time the broad market consistently — there are no famous investors that got rich by consistently knowing what the broad market would do next. This only makes sense, as there are just too many variables in the broad market. But there are many famous investors who got rich analyzing individual securities, and this is where you should put your focus. You can get an edge in individual securities. Joe Springer was the number 1 ranked stock analyst in the world by tipranks.com, and on most days is still ranked in the top 5%. Joe is a Certified Technical Trainer, and enjoys teaching about the stock market as well as managing portfolios. If you would like to follow Joe on Twitter, his handle is @JoeSpringer.